Royalty and other income |
12 Months Ended |
---|---|
Jul. 31, 2020 | |
Other Income and Expenses [Abstract] | |
Royalty and other income |
Note 14 - Royalty and other income The Company had a license agreement with Qiagen that began in 2005, whereby the Company earned quarterly running royalties on the net sales of Qiagen products subject to a license until the underlying patent expired in April 2018. During the years ended July 31, 2020, 2019 and 2018, the Company recorded royalty income under the agreement of approximately $0, $0 and $712 respectively, which is included in the Life Sciences products segment. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|